NCT01625156View on ClinicalTrials.gov

Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

October 31, 2015

Conditions
Adult Solid Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Temsirolimus

Given IV

DRUG

Tivantinib

Given PO

Trial Locations (2)

53226

Wisconsin Clinical Cancer Center, Milwaukee

53792

University of Wisconsin Hospital and Clinics, Madison

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01625156 - Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery | Biotech Hunter | Biotech Hunter